

Status: Currently Official on 14-Feb-2025

Official Date: Official as of 01-May-2020

Document Type: USP Monographs

DocId: GUID-33F9F616-79C8-4C5F-837C-3F4D8A06736A_4_en-US


DOI: https://doi.org/10.31003/USPNF_M13880_04_01

DOI Ref: frj9j

© 2025 USPC

Do not distribute

Cefaclor

 $C_{15}H_{14}ClN_3O_4S \cdot H_2O$

385.82

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, monohydrate, [6R-[6 α ,7 β (R*)]]-; (6R,7R)-7-[(R)-2-Amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate CAS RN®: 70356-03-5; UNII: 69K7K19H4L.

Anhydrous

367.80 CAS RN®: 53994-73-3; UNII: 3Z6FS3IK0K.

DEFINITION

Cefaclor has a potency of NLT 950 µg/mg and NMT 1020 µg/mg of cefaclor ($C_{15}H_{14}ClN_3O_4S$), calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

- A. **SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: **197K**▲ (CN 1-MAY-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Mobile phase: Dissolve 1 g of [sodium 1-pentanesulfonate](#) in a mixture of 780 mL of [water](#) and 10 mL of [triethylamine](#). Adjust with [phosphoric acid](#) to a pH of 2.5 ± 0.1 , and add 220 mL of [methanol](#).

System suitability solution: 0.3 mg/mL of [USP Cefaclor RS](#) and 0.3 mg/mL of [USP Cefaclor Delta-3 Isomer RS](#) in *Mobile phase*

Standard solution: 0.3 mg/mL of [USP Cefaclor RS](#) in *Mobile phase*. Sonicate briefly, if necessary, to achieve dissolution, and avoid heating the solution. Use within 8 h if stored at room temperature or within 20 h if stored at 5°.

Sample solution: 0.3 mg/mL of Cefaclor in *Mobile phase*. Sonicate briefly, if necessary, to achieve dissolution, and avoid heating the solution. Use within 8 h if stored at room temperature or within 20 h if stored at 5°.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 265 nm

Column: 4.6-mm × 25-cm; 5-µm packing [L1](#)

Flow rate: 1.5 mL/min

Injection volume: 20 µL

System suitability

Sample: *System suitability solution*

[NOTE—The relative retention times for cefaclor and cefaclor delta-3 isomer are about 1.0 and 1.35, respectively.]

Suitability requirements

Resolution: NLT 2.5 between the cefaclor peak and the cefaclor delta-3 isomer peak

Tailing factor: NMT 1.5 for the cefaclor peak

Relative standard deviation: NMT 0.73% for the cefaclor peak

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the potency, in µg/mg, of cefaclor ($C_{15}H_{14}ClN_3O_4S$) in the portion of Cefaclor taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P$$

r_U = peak area from the *Sample solution*

r_s = peak area from the *Standard solution*

C_s = concentration of [USP Cefaclor RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Cefaclor in the *Sample solution* (mg/mL)

P = designated potency of [USP Cefaclor RS](#) (µg/mg)

Acceptance criteria: 950–1020 µg/mg on the anhydrous basis

IMPURITIES

• ORGANIC IMPURITIES

Diluent: 2.4 g/L of [monobasic sodium phosphate](#) in [water](#), adjusted with [phosphoric acid](#) to a pH of 2.5

Solution A: 6.9 g/L of [monobasic sodium phosphate](#) in [water](#); adjusted with [phosphoric acid](#) to a pH of 4.0

Solution B: [Acetonitrile](#) and *Solution A* (45:55), degassing for NMT 2 min

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	95	5
30	75	25
45	0	100
55	0	100
60	95	5
70	95	5

Standard solution: 0.05 mg/mL of [USP Cefaclor RS](#) in *Diluent*. Sonicate briefly, if necessary, to dissolve, and avoid heating. Use within 18 h if stored at room temperature, or within 24 h when stored at 5°.

System suitability solution: 0.05 mg/mL of [USP Cefaclor RS](#) and 0.05 mg/mL of [USP Cefaclor Delta-3 Isomer RS](#) in *Diluent*

Sample solution: 5 mg/mL of Cefaclor in *Diluent*. Sonicate briefly, if necessary, to dissolve, and avoid heating. Use within 2 h when stored at room temperature or within 20 h when stored at 5°.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 25-cm; 5-µm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 20 µL

System suitability

Sample: *System suitability solution*

[NOTE—The relative retention times for cefaclor and cefaclor delta-3 isomer are 1.0 and 0.85, respectively.]

Suitability requirements

Resolution: NLT 2.0 between cefaclor delta-3 isomer and cefaclor

Tailing factor: NMT 1.2 for the cefaclor peak

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each cefaclor related compound in the portion of Cefaclor taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times P \times F \times 100$$

r_u = peak response of an individual related compound from the *Sample solution*

r_s = peak response of the cefaclor peak from the *Standard solution*

C_s = concentration of [USP Cefaclor RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Cefaclor in the *Sample solution* (mg/mL)

P = designated potency of [USP Cefaclor RS](#) (µg/mg)
 F = conversion factor, 0.001 mg/µg

Acceptance criteria

Individual impurities: NMT 0.5% of any individual cefaclor related compound

Total impurities: NMT 2.0% of total cefaclor related compounds

In an acceptable determination, the difference between duplicate determinations of total cefaclor related compounds is NMT 0.2% absolute, or the variation from the mean of the two values is NMT 10%, whichever is greater.

SPECIFIC TESTS

- [CRYSTALLINITY \(695\)](#): Meets the requirements
- [pH \(791\)](#)
Sample: 25-mg/mL aqueous suspension
Acceptance criteria: 3.0–4.5
- [WATER DETERMINATION \(921\)](#), *Method I*: 3.0%–6.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- [USP REFERENCE STANDARDS \(11\)](#).

[USP Cefaclor RS](#)

[USP Cefaclor Delta-3 Isomer RS](#)

(6*R*,7*R*)-7-[[[(2*R*)-(Aminophenylacetyl)]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid.

$C_{15}H_{14}ClN_3O_4S$ 367.80

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CEFACLOR	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(6)

Current DocID: GUID-33F9F616-79C8-4C5F-837C-3F4D8A06736A_4_en-US

DOI: https://doi.org/10.31003/USPNF_M13880_04_01

DOI ref: [frj9j](#)